|
1
|
Kelley JR and Duggan JM: Gastric cancer
epidemiology and risk factors. J Clin Epidemiol. 56:1–9. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Banerjee D, Mayer-Kuckuk P, Capiaux G,
Budak-Alpdogan T, Gorlick R and Bertino JR: Novel aspects of
resistance to drugs targeted to dihydrofolate reductase and
thymidylate synthase. Biochim Biophys Acta. 1587:164–173. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gottesman MM: Mechanisms of cancer drug
resistance. Annu Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Larsen AK, Escargueil AE and Skladanowski
A: Resistance mechanisms associated with altered intracellular
distribution of anticancer agents. Pharmacol Ther. 85:217–229.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fuertes MA, Alonso C and Pérez JM:
Biochemical modulation of Cisplatin mechanisms of action:
enhancement of antitumor activity and circumvention of drug
resistance. Chem Rev. 103:645–662. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Konishi H, Usui T, Sawada H, Uchino H and
Kidani Y: Effects of anticancer platinum compounds on
Escherichia coli strains with normal and defective DNA
repair capacity. Gann. 72:627–630. 1981.PubMed/NCBI
|
|
7
|
Beck DJ, Popoff S, Sancar A and Rupp WD:
Reactions of the UVRABC excision nuclease with DNA damaged by
diamminedichloroplatinum(II). Nucleic Acids Res. 13:7395–7412.
1985. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fram RJ, Cusick PS and Marinus MG: Studies
on mutagenesis and repair induced by platinum analogs. Mutat Res.
173:13–18. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kartalou M and Essigmann JM: Mechanisms of
resistance to cisplatin. Mutat Res. 478:23–43. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Brown R, Hirst GL, Gallagher WM, et al:
hMLH1 expression and cellular responses of ovarian tumour cells to
treatment with cytotoxic anticancer agents. Oncogene. 15:45–52.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fink D, Nebel S, Aebi S, et al: The role
of DNA mismatch repair in platinum drug resistance. Cancer Res.
56:4881–4886. 1996.PubMed/NCBI
|
|
12
|
Vaisman A, Varchenko M, Umar A, et al: The
role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and
oxaliplatin resistance: correlation with replicative bypass of
platinum-DNA adducts. Cancer Res. 58:3579–3585. 1998.PubMed/NCBI
|
|
13
|
Kim YJ, Kwak CI, Gu YY, Hwang IT and Chun
JY: Annealing control primer system for identification of
differentially expressed genes on agarose gels. Biotechniques.
36:424–426. 2004.PubMed/NCBI
|
|
14
|
Hwang KC, Cui XS, Park SP, et al:
Identification of differentially regulated genes in bovine
blastocysts using an annealing control primer system. Mol Reprod
Dev. 69:43–51. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee KY, Huang SM, Li S and Kim JM:
Identification of differentially expressed genes in papillary
thyroid cancers. Yonsei Med J. 50:60–67. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Le TV, Seo Y, Ryu CJ, Lee HR and Park HJ:
Increased expression of p27 is associated with the cisplatin
resistance in gastric cancer cell line YCC-3. Arch Pharm Res.
33:1127–1132. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Altschul SF, Gish W, Miller W, Myers EW
and Lipman DJ: Basic local alignment search tool. J Mol Biol.
215:403–410. 1990. View Article : Google Scholar
|
|
18
|
Yoon IS, Chung JH, Hahm SH, et al:
Ribosomal protein S3 is phosphorylated by Cdk1/cdc2 during G2/M
phase. BMB Rep. 44:529–534. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huang M, Qian F, Hu Y, Ang C, Li Z and Wen
Z: Chromatin-remodelling factor BRG1 selectively activates a subset
of interferon-alpha-inducible genes. Nat Cell Biol. 4:774–781.
2002. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Deblandre GA, Marinx OP, Evans SS, et al:
Expression cloning of an interferon-inducible 17-kDa membrane
protein implicated in the control of cell growth. J Biol Chem.
270:23860–23866. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kang HC, Kim IJ, Park JH, et al:
Identification of genes with differential expression in acquired
drug-resistant gastric cancer cells using high-density
oligonucleotide microarrays. Clin Cancer Res. 10:272–284. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Luker KE, Pica CM, Schreiber RD and
Piwnica-Worms D: Overexpression of IRF9 confers resistance to
antimicrotubule agents in breast cancer cells. Cancer Res.
61:6540–6547. 2001.PubMed/NCBI
|
|
23
|
Yang G, Xu Y, Chen X and Hu G: IFITM1
plays an essential role in the antiproliferative action of
interferon-gamma. Oncogene. 26:594–603. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sentani K, Oue N, Kondo H, et al:
Increased expression but not genetic alteration of BRG1, a
component of the SWI/SNF complex, is associated with the advanced
stage of human gastric carcinomas. Pathobiology. 69:315–320. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kothandapani A, Gopalakrishnan K, Kahali
B, Reisman D and Patrick SM: Downregulation of SWI/SNF chromatin
remodeling factor subunits modulates cisplatin cytotoxicity. Exp
Cell Res. 318:1973–1986. 2012. View Article : Google Scholar : PubMed/NCBI
|
